Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 3:21 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 1,551 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Ulcerative Clear all

Conditions: Diabetic Foot Ulcer (DFU), Amnio-Maxx
Interventions: Amnio-Maxx® Dual Layer Amnion Patch, Standard of Care (Investigator Choice); Biological · Other
Lead sponsor: Royal Biologics; Industry
Eligibility: 18 Years and older
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 8
States / cities: Burbank, California • Miami, Florida • Stone Mountain, Georgia + 5 more

Conditions: Diabetic Foot Ulcer
Interventions: NOX1416 and SOC, SOC (Standard of care); Drug · Procedure
Lead sponsor: NOxy Health Products, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 13
States / cities: Phoenix, Arizona • Tucson, Arizona • Coral Gables, Florida + 9 more

Conditions: Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Interventions: Probiotic Mixture, Placebo; Dietary Supplement
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetic Foot, Leg Ulcer, Decubitus Ulcer
Interventions: Not listed
Lead sponsor: Southwest Regional Wound Care Center; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2018
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Non-Diabetic Patients, Wound Leg, Chronic Ulcer Leg/Foot
Interventions: Not listed
Lead sponsor: Chandan Sen; Other
Eligibility: 30 Years and older
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2023
U.S. locations: 3
States / cities: Indianapolis, Indiana • Columbus, Ohio

Conditions: Ulcerative Colitis
Interventions: Asacol (mesalamine); Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Colitis, Ulcerative
Interventions: placebo, MultiStem low dose, MultiStem high dose; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 37
States / cities: San Francisco, California • Lafayette, Colorado • Lakewood, Colorado + 24 more

Conditions: Pyoderma Gangrenosum
Interventions: gevokizumab, Placebo, gevokizumab open-label; Drug
Lead sponsor: XOMA (US) LLC; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 7
States / cities: Oceanside, California • Tampa, Florida • Macon, Georgia + 4 more

Conditions: IBD (Inflammatory Bowel Disease), IBS - Irritable Bowel Syndrome, Crohn Disease (CD), UC - Ulcerative Colitis
Interventions: ALPCO Calprotectin CLIA; Device
Lead sponsor: American Laboratory Products Company; Industry
Eligibility: 22 Years and older
Enrollment: 121 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Salem, New Hampshire

Conditions: Ulcerative Colitis, Crohn's Disease
Interventions: No intervention; Other
Lead sponsor: Takeda; Industry
Eligibility: 65 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Diabetic Foot Ulcers
Interventions: MEBO Wound Ointment, Standard of Care (sterile saline moistened gauze); Drug · Procedure
Lead sponsor: Skingenix, Inc.; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: New Haven, Connecticut • Boston, Massachusetts

Conditions: Crohn Disease, Colitis, Ulcerative
Interventions: TEV-48574 Dose Regimen A, TEV-48574 Dose Regiment B; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 18
States / cities: San Diego, California • Kissimmee, Florida • Orlando, Florida + 15 more

Conditions: Ulcerative Colitis
Interventions: APL-1401, Placebo; Drug
Lead sponsor: Jiangsu Yahong Meditech Co., Ltd aka Asieris; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 4
States / cities: Corona, California • Tampa, Florida • Marrero, Louisiana + 1 more

Conditions: Chronic Wounds
Interventions: Swabs; Other
Lead sponsor: Systagenix Wound Management; Industry
Eligibility: 18 Years and older
Enrollment: 141 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Colitis Ulcerative, Crohn's Disease
Interventions: balinatunfib, balinatunfib-matching placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 19 Years to 77 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Southlake, Texas

Conditions: Diabetic Foot Ulcer
Interventions: Spatial Frequency Domain Imaging (SFDI); Device
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diabetic Neuropathy
Interventions: Neuropathy/Ulcer Homeopathic topical cream; Other
Lead sponsor: Calvary Hospital, Bronx, NY; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Diabetic Foot Ulcer
Interventions: MIST Therapy, SOC - Standard of Care; Device · Other
Lead sponsor: Celleration, Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: PVD, Arterial Ulcers
Interventions: High pressure intermittent pneumatic compression (HPIPC), Excercise; Device · Behavioral
Lead sponsor: Calvary Hospital, Bronx, NY; Other
Eligibility: 18 Years to 90 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: IBD (Inflammatory Bowel Disease), IBS (Irritable Bowel Syndrome), Gastrointestinal Symptoms
Interventions: Not listed
Lead sponsor: DiaSorin Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Scleroderma, Digital Ulcers
Interventions: Riociguat, Placebo; Drug
Lead sponsor: Dinesh Khanna, MD, MS; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 5
States / cities: Washington D.C., District of Columbia • Ann Arbor, Michigan • New York, New York + 2 more

Conditions: Venous Reflux
Interventions: VenaSeal™ System, Endothermal Ablation (ETA), Surgical Stripping; Device · Procedure
Lead sponsor: Medtronic Endovascular; Industry
Eligibility: 18 Years and older
Enrollment: 506 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 12
States / cities: Prescott Valley, Arizona • Tucson, Arizona • Fresno, California + 9 more

Conditions: Ulcerative Colitis, Crohn's Disease
Interventions: Chromoendoscopy with magnification; Procedure
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Diabetic Foot Ulcers
Interventions: ofloxacin, MSI-78; Drug
Lead sponsor: Abeona Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 342 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 1996
U.S. locations: 1
States / cities: Seattle, Washington

Search by objective public record fields.

Effect of Amnio-Maxx on the Healing Rate of Chronic Diabetic Foot Ulcers.

NOX1416 in Treatment of Chronic Non-Healing Diabetic Foot Ulcers

Effect of a Probiotic Mixture on the Gut Microbiome and Fatigue in Patients With Quiescent Inflammatory Bowel Disease

Obtaining and Storing Standard of Care Wound Biopsies for Immediate or Future Wound-Related Scientific Study

Role of Tissue Oxygenation and the miR-210 Gene In Wound Healing

Once Daily Versus Conventional Dosing of Asacol in the Maintenance of Quiescent Ulcerative Colitis

A Study To Investigate The Safety And Possible Clinical Benefit Of Multistem(r) In Patients With Moderate To Severe Ulcerative Colitis

An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum

ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects

A Study on Infections in Adults With Ulcerative Colitis/Crohn's Disease

A Clinical Study of the Safety and Efficacy of MEBO® Wound Ointment in Subjects With Diabetic Foot Ulcers (Pilot)

A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease

A Phase 1b Study to Evaluate APL-1401 in Patients With Moderately to Severely Active Ulcerative Colitis

Swab Sample Collection for the Detection of Bacterial Proteases

A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Disease or Ulcerative Colitis (SPECIFI-IBD-LTS)

Spatial Frequency Domain Imaging (SFD) for Assessment of Diabetic Foot Ulcer Development and Healing

Effects of a Homeopathic Anti-inflammatory Topical Cream on Ulcers and Neuropathy in the Diabetic Foot

RESPOND Restoring Equilibrium and Wound Stimulation to Promote Healing Of Non-healing DFUs

Effect of HPIPC for the Treatment of Ischemic Ulcers in Subjects With PAD

Specimen and Data Collection for a Novel Biomarker Combination for the Differential Diagnosis of Inflammatory Bowel Disease and Irritable Bowel Syndrome.

Riociguat in Scleroderma Associated Digital Ulcers

VenaSeal Spectrum: Global Post-Market Randomized Controlled Trial

Chromoendoscopy for Ulcerative Colitis Surveillance

MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers